{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T18:11:00Z","timestamp":1768587060433,"version":"3.49.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.bioorg.2023.106499","type":"journal-article","created":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T19:15:19Z","timestamp":1680376519000},"page":"106499","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Novel 4-Amino-Quinazoline moieties ligated Platinum(IV) prodrugs overcome cisplatin resistance in EGFRWT human lung cancer"],"prefix":"10.1016","volume":"135","author":[{"given":"Rui","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huihua","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2023.106499_b0005","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2023.106499_b0010","article-title":"Lung cancer","volume":"365","author":"Neal","year":"2019","journal-title":"B. M. J."},{"key":"10.1016\/j.bioorg.2023.106499_b0015","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1016\/j.apsb.2022.02.029","article-title":"Synthesis of selective PAK4 inhibitors for lung metastasis of lung cancer and melanoma cells","volume":"12","author":"Song","year":"2022","journal-title":"Acta. Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2023.106499_b0020","doi-asserted-by":"crossref","unstructured":"D. Deb, A.C. Moore, U.B. Roy, The 2021 global lung cancer therapy landscape, J. Thorac. Oncol. 17 (2022) 931\u2013936.","DOI":"10.1016\/j.jtho.2022.03.018"},{"key":"10.1016\/j.bioorg.2023.106499_b0025","article-title":"Pathogenesis and therapeutic strategy in platinum resistance lung cancer","volume":"1876","author":"Lv","year":"2021","journal-title":"BBA-Rev. Cancer"},{"key":"10.1016\/j.bioorg.2023.106499_b0030","doi-asserted-by":"crossref","unstructured":"J. Hack, S.J. Crabb, Platinum-based chemotherapy 'rechallenge' in advanced non-ovarian solid malignancies, Clin. Oncol. 34 (2022) e329\u2013e344.","DOI":"10.1016\/j.clon.2022.02.015"},{"key":"10.1016\/j.bioorg.2023.106499_b0035","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1021\/acs.jmedchem.9b01223","article-title":"Platinum-based modification of styrylbenzylsulfones as multifunctional antitumor agents: Targeting the RAS\/RAF pathway, enhancing antitumor activity, and overcoming multidrug resistance","volume":"63","author":"Liu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106499_b0040","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.765552","article-title":"Quinazoline derivatives as potential therapeutic agents in urinary bladder cancer therapy","volume":"9","author":"Wdowiak","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.bioorg.2023.106499_b0045","doi-asserted-by":"crossref","first-page":"12983","DOI":"10.1039\/C6DT01414C","article-title":"Platinum(iv) anticancer prodrugs - hypotheses and facts","volume":"45","author":"Gibson","year":"2016","journal-title":"Dalton. T."},{"issue":"5","key":"10.1016\/j.bioorg.2023.106499_b0050","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1021\/acs.chemrev.5b00597","article-title":"The next generation of platinum drugs: Targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs","volume":"116","author":"Johnstone","year":"2016","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bioorg.2023.106499_b0055","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1021\/cr4004314","article-title":"Synthetic methods for the preparation of platinum anticancer complexes","volume":"114","author":"Wilson","year":"2014","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bioorg.2023.106499_b0060","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1021\/bc070031k","article-title":"Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature","volume":"19","author":"Mukhopadhyay","year":"2008","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.bioorg.2023.106499_b0065","doi-asserted-by":"crossref","first-page":"9035","DOI":"10.1021\/acs.jmedchem.6b00955","article-title":"A lipophilic Pt(IV) oxaliplatin derivative enhances antitumor activity","volume":"59","author":"Abu Ammar","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106499_b0070","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejmech.2017.01.032","article-title":"Mono-functionalized glycosylated platinum(IV) complexes possessed both pH and redox dual-responsive properties: Exhibited enhanced safety and preferentially accumulated in cancer cells in vitro and in vivo","volume":"128","author":"Ma","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106499_b0075","doi-asserted-by":"crossref","first-page":"7933","DOI":"10.1021\/acs.jmedchem.2c00472","article-title":"Platinum(IV) prodrugs with cancer stem cell inhibitory effects on lung cancer for overcoming drug resistance","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106499_b0080","doi-asserted-by":"crossref","unstructured":"P. Fronik, M. Gutmann, P. Vician, M. Stojanovic, A. Kastner, P. Heffeter, C. Pirker, B.K. Keppler, W. Berger, C.R. Kowol, A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance, Commu. Chem. 5 (2022) 46(1\u201313).","DOI":"10.1038\/s42004-022-00661-z"},{"key":"10.1016\/j.bioorg.2023.106499_b0085","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1039\/C8SC00428E","article-title":"Triple action Pt(IV) derivatives of cisplatin: A new class of potent anticancer agents that overcome resistance","volume":"9","author":"Petruzzella","year":"2018","journal-title":"Chem. Sci."},{"key":"10.1016\/j.bioorg.2023.106499_b0090","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1021\/jm400463q","article-title":"Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer","volume":"56","author":"Han","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106499_b0095","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1021\/acs.jmedchem.1c01827","article-title":"Discovery of potent PROTACs targeting EGFR mutants through the optimization of covalent EGFR ligands","volume":"65","author":"Zhao","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106499_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113300","article-title":"Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR\/CAIX dual inhibitors","volume":"216","author":"Zhang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106499_b0105","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.lungcan.2019.08.001","article-title":"EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations","volume":"136","author":"Tang","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bioorg.2023.106499_b0110","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.ejmech.2018.06.024","article-title":"Novel series of 6-(2-substitutedacetamido)-4-anilinoquinazolines as EGFR-ERK signal transduction inhibitors in MCF-7 breast cancer cells","volume":"155","author":"Ismail","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106499_b0115","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejmech.2015.11.016","article-title":"4-Arylamino-6-nitroquinazolines: Synthesis and their activities against neglected disease leishmaniasis","volume":"108","author":"Saad","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106499_b0120","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.21037\/apm-22-671","article-title":"Pembrolizumab for the better treatment of EGFR-mutant T790M-negative advanced lung adenocarcinoma patients than dual treatment of pemetrexed plus platinum after tyrosine kinase inhibitor treatment failure","volume":"11","author":"Lu","year":"2022","journal-title":"Ann. Palliat. Med."},{"key":"10.1016\/j.bioorg.2023.106499_b0125","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1021\/acs.jmedchem.6b01907","article-title":"Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2- ylmethoxy)phenyl)-1H-pyrazolo3,4-dpyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a novel irreversible EGFR mutant kinase inhibitor with a distinct binding mode","volume":"60","author":"Wang","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106499_b0130","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1021\/jm901453q","article-title":"Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)- N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer","volume":"53","author":"Cai","year":"2010","journal-title":"J. Med. Chem."},{"key":"#cr-split#-10.1016\/j.bioorg.2023.106499_b0135.1","doi-asserted-by":"crossref","unstructured":"(a) M.M. Hamed, S.S. Darwish, J. Herrmann, A.H. Abadi, M. Engel, First bispecific inhibitors of the epidermal growth factor receptor kinase and the NF-\u03baB activity as novel anticancer agents, J. Med. Chem. 60 (2017) 2853\u22122868.","DOI":"10.1021\/acs.jmedchem.6b01774"},{"key":"#cr-split#-10.1016\/j.bioorg.2023.106499_b0135.2","doi-asserted-by":"crossref","unstructured":"(b) Y.G. Zheng, J.Su, C.Y. Gao, P. Jiang, L. An, Y.S. Xue, J. Gao, Y. Liu, Design, synthesis, and biological evaluation of novel 4-anilinoquinazoline derivatives bearing amino acid moiety as potential EGFR kinase inhibitors, Eur. J. Med. Chem. 130 (2017) 393\u2212405.","DOI":"10.1016\/j.ejmech.2017.02.061"},{"key":"#cr-split#-10.1016\/j.bioorg.2023.106499_b0135.3","doi-asserted-by":"crossref","unstructured":"(c) N. Yao, C-R. Wang, M-Q. Liu, Y-J. Li, Wi-M. Chen, Z-Q. Li, Q. Qi, J-J. Lu, C-L. Fan, M-F. Chen, M. Qi, X-B. Li, J. Hong, D-M. Zhang, W-C. Ye, Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth, Signal Transduct. Tar. 5 (2020) 214.","DOI":"10.1038\/s41392-020-00251-2"},{"key":"10.1016\/j.bioorg.2023.106499_b0140","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.bioorg.2018.01.035","article-title":"New acrylamide-substituted quinazoline derivatives with enhanced potency for the treatment of EGFR T790M-mutant non-small-cell lung cancers","volume":"77","author":"Liu","year":"2018","journal-title":"Biorgan. Chem."},{"key":"10.1016\/j.bioorg.2023.106499_b0145","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejmech.2018.01.090","article-title":"6,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells","volume":"147","author":"Zhang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106499_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112269","article-title":"Targeting RAS-RAF pathway significantly improves antitumor activity of Rigosertib-derived platinum(IV) complexes and overcomes cisplatin resistance","volume":"194","author":"Liu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106499_b0155","doi-asserted-by":"crossref","first-page":"14692","DOI":"10.1021\/acs.jmedchem.2c01224","article-title":"Pt(IV)-deferasirox prodrug combats DNA damage repair by regulating RNA N6-methyladenosine methylation","volume":"65","author":"Pan","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106499_b0160","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ejmech.2019.02.041","article-title":"New NSAID-Pt(IV) prodrugs to suppress metastasis and invasion of tumor cells and enhance anti-tumor effect in vitro and in vivo","volume":"167","author":"Song","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106499_b0165","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejmech.2019.03.030","article-title":"2,4-disubstituted quinazolines targeting breast cancer cells via EGFR-PI3K","volume":"172","author":"Li","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106499_b0170","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1021\/acs.jmedchem.9b00128","article-title":"Fuplatin: An efficient and low-toxic dual-prodrug","volume":"62","author":"Zhang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106499_b0175","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1021\/acsnano.1c06777","article-title":"Peroxidase-like active nanomedicine with dual glutathione depletion property to restore oxaliplatin chemosensitivity and promote programmed cell death","volume":"16","author":"Wu","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.bioorg.2023.106499_b0180","doi-asserted-by":"crossref","first-page":"6096","DOI":"10.1021\/acs.jmedchem.0c00343","article-title":"Anticancer Melatplatin Prodrugs: High effect and low toxicity, MT1-ER-target and immune response in vivo","volume":"63","author":"Song","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106499_b0185","first-page":"857","article-title":"Mitochondria, bioenergetics and apoptosis in cancer, Trends","volume":"3","author":"Burke","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.bioorg.2023.106499_b0190","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.semcdb.2019.05.022","article-title":"Mitochondria as playmakers of apoptosis, autophagy and senescence","volume":"98","author":"Abatea","year":"2020","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.bioorg.2023.106499_b0195","doi-asserted-by":"crossref","unstructured":"N.M. Andrews Wright, G.D. Goss, Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer, Transl. Lung Cancer Res. 8 (2019) S247\u2013S264.","DOI":"10.21037\/tlcr.2019.06.01"},{"key":"10.1016\/j.bioorg.2023.106499_b0200","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.bioorg.2023.106499_b0205","first-page":"1404","article-title":"Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC, Canc","volume":"3","author":"Walter","year":"2013","journal-title":"Discov."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206823001591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206823001591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:45:14Z","timestamp":1758617114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206823001591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":43,"alternative-id":["S0045206823001591"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2023.106499","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel 4-Amino-Quinazoline moieties ligated Platinum(IV) prodrugs overcome cisplatin resistance in EGFRWT human lung cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2023.106499","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106499"}}